GDC-4198 Clinical Trials (2026): 1 Studies for Breast Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 GDC-4198 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Breast Cancer) and 285 total planned enrollment. 1 GDC-4198 clinical trial is actively recruiting at 16 U.S. sites across 12 states. Most recent activity: NCT07100106 (Aug 2028).
Where to Participate: All GDC-4198 Trial Sites in the U.S. (16 sites across 12 states)
Every actively recruiting GDC-4198trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | City of Hope | Duarte91010 | NCT07100106 | Map |
| CA | City of Hope - Orange County Lennar Foundation Cancer Center | Irvine92618 | NCT07100106 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093-1503 | NCT07100106 | Map |
| CA | UCSF Helen Diller Family CCC | San Francisco94158 | NCT07100106 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT07100106 | Map |
| GA | Winship Cancer Institute of Emory University | Atlanta30322-1013 | NCT07100106 | Map |
| IL | City of Hope® Cancer Center Chicago | Zion60099 | NCT07100106 | Map |
| ME | Barbara Ann Karmanos Cancer Institute | Detroit48201-2013 | NCT07100106 | Map |
| MO | Washington University Siteman Cancer Center | St Louis63110-1010 | NCT07100106 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08901-1914 | NCT07100106 | Map |
| NY | New York Cancer & Blood Specialists | East Patchogue11772 | NCT07100106 | Map |
| PA | University of Pennsylvania - Abramson Cancer Center | Philadelphia19104 | NCT07100106 | Map |
| PA | UPMC - Hillman Cancer Center | Pittsburgh15213-3108 | NCT07100106 | Map |
| TN | Vanderbilt Breast Center at One Hundred Oaks | Nashville37204-3609 | NCT07100106 | Map |
| TX | Texas Oncology (Worth) - USOR | Dallas75246-2003 | NCT07100106 | Map |
| VA | Virginia Oncology Associates (Norfolk) - USOR | Norfolk23502-2800 | NCT07100106 | Map |
GDC-4198 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1/P2 | 1 | 1 |
Recruiting GDC-4198 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07100106 | MoonROSEA Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | P1/P2 | Breast Cancer | 285 | Oct 2025 |
All GDC-4198 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07100106 | MoonROSE | A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | P1/P2 | recruiting | 285 | Genentech, Inc. | Oct 2025 |
GDC-4198 clinical trials: frequently asked questions
- How many GDC-4198 clinical trials are there?
- 1 GDC-4198 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are GDC-4198 clinical trials recruiting in 2026?
- Yes — 1 GDC-4198 trial is actively recruiting in 2026, with 16 U.S. sites across 12 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is GDC-4198 being studied for?
- GDC-4198 is being studied for Breast Cancer. The trials are grouped by indication on this page.
- Who sponsors GDC-4198 clinical trials?
- The lead sponsor across the most GDC-4198 trials is Genentech, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming GDC-4198as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: